A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain

• I. Márquez-Rodas ^[1] ; A. Arance ^[2] ; A. Berrocal ^[3] ; C. L. Larios ^[5] ; J. Curto-García ^[5] ; I. X. Campos-Tapias ^[6] ; A. B. Blanca ^[6] ; S. Martin-Algarra ^[4]
  1. [1] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  2. [2] Hospital Clinic Barcelona

     Hospital Clinic Barcelona

     Barcelona, España

     
  3. [3] Hospital General Universitario de Valencia

     Hospital General Universitario de Valencia

     Valencia, España

     
  4. [4] Clínica Universitaria de Navarra

     Clínica Universitaria de Navarra

     Pamplona, España

     
  5. [5] MFAR S.L., Barcelona
  6. [6] AMGEN S.A., Barcelona

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 12 (December), 2019, págs. 1754-1762
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Purpose To describe patient characteristics by disease stage, resectability status and current treatment management after first diagnosis of IIIB to IV1c advanced (AM)/metastatic melanoma (MM).

    Methods/patients Multicentre, retrospective study based on data from medical charts of patients > 18 years at MM first diagnosis, visited by oncologists at 4 reference centres in Spain: Hospital Universitario Gregorio Marañón (Madrid), Hospital General de Valencia (Valencia), Clínica Universidad de Navarra (Pamplona), and Hospital Clínic (Barcelona).

    Results Metastatic non-visceral melanoma (IIIB, IIIC, IV M1a) was reported in 139 (48.6%) patients and 40.9% (n = 117) were diagnosed with IV-M1c disease. 160 (55.9%) metastases were resectable. Available therapies under clinical practice were used in 210 patients; 74 were treated under clinical trials (CT). Intention-to-cure surgery (47.6%) was the most common treatment at time of MM diagnosis. Systemic (45.1% overall) therapy included chemo-, targeted- and immunotherapy (19.6%, 14.3%, 8.4%, respectively). At time of data collection, 26 patients were still alive and 120 had progressed to IV-M1c. Median overall survival (OS) was significantly larger in IIIB patients, 28.9 m (25.2–32.7); the shortest for IV-M1c patients, 11.0 m (8.7–13.3).

    Conclusions Novel treatments are undoubtedly a major step forward in AM/MM, however these are often only available in the CT setting because early stages of development or country-specific regulations. Further prospective studies and multifactorial analysis should be performed to clearly identify possible clinical associations for outcome in Spanish patients with AM/MM.